Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14829729 | 0.92 | CYP19A1 (0.52) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL6509060 | 0.92 | CYP1A1 (0.56) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| Hesperetin SCHEMBL20164911 | 0.88 | CYP19A1 (0.79) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| Hesperetin SCHEMBL5202127 | 0.88 | CYP19A1 (0.79) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL18339272 | 0.87 | CYP19A1 (0.45) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL27205452 | 0.87 | CYP19A1 (0.45) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL7200862 | 0.86 | CYP1A1 (0.54) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL16151244 | 0.86 | KDM4E (0.54) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL2781922 | 0.86 | KDM4E (0.54) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 | |
| SCHEMBL8249167 | 0.86 | KDM4E (0.54) | CYP19A1CYP1A1CYP1A2CYP1B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042962-A1 | Vascular Calcification Prevention and Treatment | Summit Innovation Labs LLC (US) | 2018-02-15 | — | — | US | claimed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | claimed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | claimed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | claimed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-20250114424-A1 | PLANT EXTRACT-BASED COMPOSITION AND ITS USE FOR TREATING GLUCOSE METABOLISM DISORDERS | ESSERRE PHARMA SRL (IT) | 2025-04-10 | — | — | US | disclosed |
| EP-3496844-B1 | VASCULAR CALCIFICATION AND CARDIOVASCULAR/ASSOCIATED DISEASES PREVENTION AND TREATMENT | Summit Innovation Labs LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023012283-A1 | PLANT EXTRACT-BASED COMPOSITION AND ITS USE FOR TREATING GLUCOSE METABOLISM DISORDERS | ESSERRE PHARMA SRL (IT) | 2023-02-09 | — | — | WO | disclosed |
| US-11357250-B2 | Treatment and prevention of diabetes and obesity | Summit Innovation Labs LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11344575-B2 | Vascular calcification prevention and treatment | Summit Innovation Labs, LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-11234918-B2 | Methods for botanical and/or algae extraction | BASF CORPORATION (US) | 2022-02-01 | — | — | US | disclosed |
| US-11039636-B2 | Treatment and prevention of bone and joint disorders | Summit Innovation Labs, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-5885969-A | INCREASING WATER SOLUBILITY AND PREVENTING CRYSTALS PRECIPITATION IN CANNED TANGERINES, ALSO PREVENT THE FADING OF NATURAL COLORING AGENTS; STORAGE STABILITY | KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) | 1999-03-23 | — | — | US | disclosed |
| WO-1998036750-A1 | ANTI-MICROBIAL PRODUCT | BTG INTERNATIONAL LIMITED (GB) | 1998-08-27 | — | — | WO | disclosed |
| EP-0825196-A2 | Enzyme-treated hesperidin, process for producing the same and method of using enzyme-treated hesperidin | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) | 1998-02-25 | — | — | EP | disclosed |
| EP-0290442-A4 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. | CHEMEX PHARMACEUTICALS INC (US) | 1990-07-03 | — | — | EP | disclosed |
| EP-0290442-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| WO-1988003805-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS | CHEMEX PHARMACEUTICALS, INC. (US) | 1988-06-02 | — | — | WO | disclosed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0065123-B1 | HARDLY SOLUBLE SALTS OF AMINOGLYCOSIDE ANTIBIOTICS | MERCK PATENT GmbH (DE) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | ALG1, ALG8, CUTA | CYP19A1 1745/4885CYP1A1 2372/4885CYP1A2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.